Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Osimertinib (TAGRISSO) (ROSY-T)

Trial Identifier: D5161N00007
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: May 2023
Primary Completion Date: February 2027
Study Completion Date: February 2027
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100142
CN Chongqing, CN, 400042
CN Shanghai, CN, 200433
CN Yangzhou, CN, 225001
CN Zhengzhou, CN, 450008
FR Villejuif Cedex, FR, 94805
GB Nottingham, GB, NG5 1PB
KR Cheongju-si, KR, 28644
KR Dong-gu, KR, 44033
KR Goyang-si, KR, 10408
KR Seongnam-si, KR, 13620
KR Seoul, KR, 03080
KR Seoul, KR, 03722
KR Seoul, KR, 06591
KR Seoul, KR, 06351
KR Seoul, KR, 5505
MY Georgetown, MY, 10450
MY Johor Bahru, MY, 81100
MY Kuantan, MY, 25100
MY Kuching, MY, 93586
PL Szczecin, PL, 70-419
TW Kaohsiung, TW, 83301
TW Taichung, TW, 40705
TW Tainan, TW, 736
TW Tainan, TW, 704
TW Taipei, TW, 112201
TW Taoyuan, TW, 333